Düşük Molekül Ağırlıklı Heparin Tedavisinin Nadir Komplikasyonu: Mesane Hematomu

Öz

Introduction: Low-molecular-weight heparin is one of the most preferred agents used in the prevention and treatment of thromboembolic disorders.   Case Report: An 85-year-old female patient was admitted for 3 days wıth ongoing and growing vaginal bleeding. Bladder hematoma and postrenal acute renal failure, rare complications of low-molecular-weight heparins, are presented in this case.   Conclusion: Patients who have complaints about vaginal bleeding or hematuria should be questioned about a detailed history and the use of low-molecular-weight heparin. Low-molecular-weight heparin in rare cases may lead to bleeding, and postrenal acute renal failure should be kept in mind.

Anahtar Kelimeler

• Low-molecular-weight heparin, bladder hematoma, acute renal failure

A Rare Complication of Low-Molecular-Weight Heparin Therapy: Bladder Hematoma

Öz

Introduction: Low-molecular-weight heparin is one of the most preferred agents used in the prevention and treatment of thromboembolic disorders.Case Report: An 85-year-old female patient was admitted for 3 days wıth ongoing and growing vaginal bleeding. Bladder hematoma and postrenal acute renal failure, rare complications of low-molecular-weight heparins, are presented in this case.Conclusion: Patients who have complaints about vaginal bleeding or hematuria should be questioned about a detailed history and the use of low-molecular-weight heparin. Lowmolecular-weight heparin in rare cases may lead to bleeding, and postrenal acute renal failure should be kept in mind

Anahtar Kelimeler

• Low-molecular-weight heparin, bladder hematoma, acute renal failure

Kaynakça

1. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular- weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A metaanalysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9. [CrossRef]
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98. [CrossRef]
3. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-7. [CrossRef]
4. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta- analysis. Am J Med 1996; 100: 269-77. [CrossRef]
5. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Eng J Med 1997; 337: 657-62. [CrossRef]
6. Spinler SA, Nawarskas JJ. Low-molecular weight heparins for acute coronary syndromes. Ann Pharmacother 1998; 32: 103-10. [CrossRef]
7. Ji H, Li SP, Cheng X, Cheng HR, Ng TB, Li P, Li NS. Antithrombotic effects of low-molecular-weight heparin calcium (LMWH-Ca) in experimental models. Gen Pharmocol 1999; 33: 207-11. [CrossRef]
8. Menzin J, Richner R, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994; 28: 271-5.

9. Deep K, Jigajinni MV, McLean AN, Fraser MH. Prophylaxis of thromboembolism in spinal injuries-results of enoxaparin used in 276 patients. Spinal Cord 2001; 39: 88-91. [CrossRef]
10. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease Educational and Research Trust; European Venous Forum; International Surgical Thrombosis Forum; International Union of Angiology; Union Internationale de Phlébologie. Prevention and treatment of venous thromboembolism-International Consensus Statement (ICS). Guidelines according to scientific evidence. Int Angiol 2006; 25: 101-61.